Bullish Case: BMY is positioned in a growing biotechnology market which projects at an 11.13% CAGR from 2023 to 2030[seedance.com]. Promising new Zeposia data[news.bms.com], an attractive 4% dividend yield[seekingalpha.com] and another drug Golcadomide in Phase II for Primary CNS Lymphoma[pharmaceutical-technology.com] show growth potential.


Show historical bullish cases

Bearish Case: BMY is currently at -34.4% from a year ago[Helium], with an unfavourable HeliumTrades AI price forecast[Helium]. Risks include stock concentration[seekingalpha.com], insider selling activity[Yahoo], and potential patent expirations[seekingalpha.com] which could harm future profits.


Show historical bearish cases

Takeaway: Unfavorable market sentiment around BMY, shown by the declining share price and insider selling[Yahoo, Helium], poses a challenge. However, the underpinning factors of new promising drug developments[news.bms.com, pharmaceutical-technology.com] and a healthy dividend yield[seekingalpha.com] indicate potential for future rewards notwithstanding potential risks.


Show historical takeaways

Potential Outcomes:

1. Successful drug developments(e.g Zeposia[news.bms.com], and Golcadomide[pharmaceutical-technology.com]) drive revenue growth and share price appreciation (60%). Strengths lie in the growing global biotech market[seedance.com] and BMY's innovative capabilities[Helium].

2. The effect of insider selling activity spooks investors, leading to a decrease in value, despite strong drug prospects. This could cause a drop in liquidity, but has potential to recover if future results are presented positively (30%)[Yahoo].

3. Low trading volumes due to mixed market sentiment keep the stock price stagnant - despite news of progress from its drug pipelines. This could be exacerbated by any negative news from competitors or the healthcare sector (10%)[Helium].


November 14, 2023


Bristol-Myers Squibb Forecast

[BMY]  Bristol-Myers Squibb
Price Forecast: BEARISH    Price Action: RANDOM (?)



Make More Profitable Trades with BMY Forecasts + Trading Strategies







BMY Balanced News:


















Correlated Stock Forecasts

Assets that tend to move strongly with BMY



MRNA Forecast + Options Trading Strategies   [MRNA]  Moderna (0.96)


ETSY Forecast + Options Trading Strategies   [ETSY]  Etsy (0.94)


QURE Forecast + Options Trading Strategies   [QURE]  uniQure (0.94)


A Forecast + Options Trading Strategies   [A]  Agilent (0.94)


ENB Forecast + Options Trading Strategies   [ENB]  Enbridge (0.93)



Uncorrelated Stock Forecasts

Assets with little price relationship to BMY



VGK Forecast + Options Trading Strategies   [VGK]  Vanguard FTSE Europe (-0.0)


PK Forecast + Options Trading Strategies   [PK]  Park Hotels & Resorts (-0.0)


XLE Forecast + Options Trading Strategies   [XLE]  Energy Select Sector SPDR (-0.01)


JDST Forecast + Options Trading Strategies   [JDST]  Direxion Daily Junior Gold Miners Index Be (-0.01)


AMGN Forecast + Options Trading Strategies   [AMGN]  AMGEN (-0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against BMY



FTI Forecast + Options Trading Strategies   [FTI]  TechnipFMC (-0.91)


DKNG Forecast + Options Trading Strategies   [DKNG]  DraftKings (-0.91)


DXJ Forecast + Options Trading Strategies   [DXJ]  WisdomTree Japan Hedged Equity (-0.92)


SPOK Forecast + Options Trading Strategies   [SPOK]  Spok (-0.92)


RELY Forecast + Options Trading Strategies   [RELY]  Remitly (-0.93)